Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6107-6116

  Hamilton, A L ^a   Eder, J P ^a   Pavlick, A C ^a   Clark, J W ^a   Liebes, L ^a   Garcia Carbonero, R ^a   Chachoua, A ^a   Ryan, D P ^a   Soma, V ^a   Farrell, K ^a   Kinchla, N ^a   Boyden, J ^a   Yee, H ^a   Zeleniuch Jacquotte, A ^a   Wright, J ^a   Elliott, P ^a   Adams, J ^a   Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEASOME; PROTEIN BCL 2; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INHIBITION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; INSOMNIA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RASH; RECOMMENDED DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UBIQUITINATION; VOMITING; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TREATMENT OUTCOME;

EID: 24944514626     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.136     Document Type: Article

References (30)

1. Nagata Y, Anan T, Yoshida T, et al: The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association. Oncogene 18:6037-6049, 1999
2. An WG, Hwang SG, Trepel JB, et al: Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276-1283, 2000
3. Alessandrini A, Chiaur DS, Pagano M: Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345, 1997
4. Lonard DM, Nawaz Z, Smith CL, et al: The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5:939-948, 2000
5. Palombella VJ, Conner EM, Fuseler JW, et al: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95:15671-15676, 1998
6. Voorhees PM, Dees EC, O'Neil B, et al: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003
7. Read MA, Neish AS, Luscinskas FW, et al: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506, 1995
8. Lane DP: The regulation of p53 function: Steiner Award Lecture. Int J Cancer 57:623-627, 1994
9. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999
10. Ling YH, Liebes L, Jiang J-D, et al: Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154, 2003
11. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849, 2002
12. Ling YH, Liebes L, Zou Y, et al: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714-33723, 2003
13. Adams J: Development of the proteasome inhibitor PS-341. The Oncologist 7:9-16, 2002
14. Papandreou C, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
15. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
16. Erlichman C, Adjei AA, Thomas JP, et al: A phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc Am Soc Clin Oncol 20:85a, 2001 (abstr 337)
17. Nix D, Pien C, Newman R, et al: Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc Am Soc Clin Oncol 20:86a, 2001 (abstr 339)
18. Lightcap ES, McCormack TA, Pien CS, et al: Proteasome inhibition measurements: Clinical application. Clin Chem 46:673-683, 2000
19. Guarino A, Rozencweig M, Kline I, et al: Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. Cancer Res 39:2204-2210, 1979
20. Muggia F, Carter S, Macdonald J: The cancer therapy evaluation program of the National Cancer Institute. Semin Oncol 8:394-402, 1981
21. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000
22. Matkowskyi K, Glover S, Benya R: Quantitative Immunohistochemistry: A new algorithm measuring cumulative signal strength and receptor number. Microscopy and Analysis 18:5-6, 2004
23. Liebes L, Potmesil M, Kim T, et al: Pharmacodynamics of topoisomerase I inhibition; western blot determination of topoisomerase I and cleavable complexes in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 4:545-557, 1998
24. Holford NHG, Sheiner LB: Kinetics of pharmacologic response. Pharmacol Ther 16:143-166, 1982
25. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
26. Ding Q, Keller JN: Proteasome inhibition in oxidative stress nerotoxicity: Implication for heat shoek proteins. J Neurochem 77:1010-1017, 2001
27. Cui J, Holmin S, Mathiesen T, et al: Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 88:239-248, 2000
28. Murwani R, Armati P: Peripheral nerve fibroblasts as a source of IL-6, TNFalpha and IL-1 and their modulation by IFNgamma. J Neurol Sci 161:99-109, 1998
29. Chauvenet AR, Shashi V, Selsky C, et al: Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 25: 316-320, 2003
30. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003